Development of vaccines for chikungunya fever

Jesse H. Erasmus, Shannan Rossi, Scott Weaver

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.

Original languageEnglish (US)
Pages (from-to)S488-S496
JournalJournal of Infectious Diseases
Volume214
DOIs
StatePublished - Dec 1 2016

Fingerprint

Chikungunya virus
Vaccines
Antigenic Variation
Culicidae
Chronic Disease
Chikungunya Fever

Keywords

  • Alphavirus
  • Arthralgia
  • Chikungunya
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Development of vaccines for chikungunya fever. / Erasmus, Jesse H.; Rossi, Shannan; Weaver, Scott.

In: Journal of Infectious Diseases, Vol. 214, 01.12.2016, p. S488-S496.

Research output: Contribution to journalArticle

@article{fa939c5aee334b90a7430ca1c77eded0,
title = "Development of vaccines for chikungunya fever",
abstract = "Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.",
keywords = "Alphavirus, Arthralgia, Chikungunya, Vaccine",
author = "Erasmus, {Jesse H.} and Shannan Rossi and Scott Weaver",
year = "2016",
month = "12",
day = "1",
doi = "10.1093/infdis/jiw271",
language = "English (US)",
volume = "214",
pages = "S488--S496",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Development of vaccines for chikungunya fever

AU - Erasmus, Jesse H.

AU - Rossi, Shannan

AU - Weaver, Scott

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.

AB - Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.

KW - Alphavirus

KW - Arthralgia

KW - Chikungunya

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85015843720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015843720&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw271

DO - 10.1093/infdis/jiw271

M3 - Article

VL - 214

SP - S488-S496

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -